However, the availability of approved and effective immunotherapies complicates the early use of CAR T cells, feasible as experimental therapy only after several registered treatments have failed, particularly in MS and AQP4-positive NMOSD. The gene discussed is AQP4; the disease is myeloid sarcoma.